Medical Oncologist
After osimertinib stops working
What Happens After — Osimertinib Stops Working?
Almost everyone on osimertinib develops resistance eventually — the cancer finds a way around the drug. Identifying how it did that is the first step, because the answer shapes what comes next.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Resistance is expected — Developing resistance to a targeted therapy over time is a known property of cancer biology, not a sign the drug failed early.
- Testing before treating — A new biopsy or blood test identifies which resistance mechanism has developed, and that result guides the next decision.
- Options still exist — Chemotherapy, targeted combinations, and clinical trials are all possible next steps depending on what resistance testing shows.
- The mechanism matters — Different resistance pathways respond to different treatments, which is why knowing the mechanism changes the recommendation.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
When osimertinib stops controlling your cancer, the next step is re-testing tumour tissue or blood to identify which resistance mechanism has developed. That result guides what comes next — platinum-based chemotherapy, a targeted combination, or a clinical trial. NCCN and ESMO guidance recommends resistance testing before choosing the next treatment.
Why does osimertinib stop working eventually?
Osimertinib stops working because cancer cells develop new molecular changes that let them grow despite the drug. This is called acquired resistance, and it is a known property of targeted therapies over time — not a sign the treatment failed early.
Resistance falls into two broad groups. In on-target resistance, the cancer develops a new mutation at the exact site where osimertinib binds — for example, a change called C797S — so the drug can no longer attach properly. In off-target resistance, the cancer keeps the original EGFR mutation but activates a completely different molecular pathway to keep growing, bypassing EGFR altogether. MET amplification and HER2 amplification are two off-target mechanisms recognised in NCCN and ESMO guidance.
In a smaller proportion of patients, the tumour undergoes a deeper change called histological transformation — shifting from non-small cell lung cancer to small cell lung cancer. This matters because small cell disease responds to a different set of treatments.
What do these terms mean?
- Resistance biopsy
- A new tissue sample taken after the cancer has progressed, to identify which molecular change has allowed it to grow past osimertinib.
- Liquid biopsy (ctDNA)
- A blood test that detects small fragments of tumour DNA in the bloodstream. It can identify some resistance mechanisms without a needle or surgical biopsy, though it does not replace tissue biopsy for all resistance types.
- On-target resistance
- A new mutation at the EGFR protein itself that prevents osimertinib from binding. The most studied example is a change called C797S at the drug's binding site.
- Off-target resistance
- The cancer keeps the original EGFR mutation but switches on a different molecular pathway to drive growth, bypassing EGFR. MET amplification and HER2 amplification are examples that can be identified by testing.
- Histological transformation
- A process in which the tumour cells change their type — most commonly from non-small cell to small cell lung cancer. This changes how the cancer behaves and which treatments are effective.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What testing happens after osimertinib stops working?
Resistance testing is the most important next step before any new treatment is chosen. NCCN and ESMO guidance recommends re-testing at progression rather than moving directly to a next-line therapy.
Your oncologist may recommend a new tissue biopsy if one is safely accessible. A liquid biopsy — a blood test — is often done at the same time and can identify several resistance mechanisms without a separate invasive procedure.
Not every case will return a clear driving mechanism. The test may show no identifiable resistance change, or more than one. That result still informs the decision, even when it does not point to a single targeted option.
What treatment options exist after osimertinib?
Platinum-based chemotherapy — typically a combination including pemetrexed — is the most established next-line option. It does not require a specific biomarker to be present, so it is available regardless of what resistance testing shows.
When MET amplification is identified, combinations targeting both EGFR and MET have shown activity in clinical studies. NCCN guidance recognises MET-directed approaches as relevant where MET amplification is confirmed at progression.
Histological transformation to small cell lung cancer requires chemotherapy regimens designed for small cell disease, rather than any further EGFR-directed therapy — one reason tissue assessment at re-biopsy matters.
Clinical trials for osimertinib-resistant disease are active and are an important option at this stage. Several trials are studying fourth-generation EGFR inhibitors and novel combinations designed specifically for this setting. Your oncologist can advise whether any open trial applies to your situation.
Questions families ask at this point
Does progression mean osimertinib was never working?
No. Resistance emerging after a period of disease control means osimertinib was working and the cancer has now adapted — that is different from the drug never working at all. EGFR-mutated lung cancers are among the most responsive to targeted therapy, and the period of control osimertinib provided has real clinical value. Resistance developing over time is an expected property of cancer biology, and it is the reason resistance testing and next-line options exist.
Can we go back on osimertinib after treating the resistance?
It depends on the resistance mechanism found. Where a specific off-target change was addressed — for example, a MET inhibitor was added to the regimen — there are circumstances where an osimertinib-containing approach may be revisited. Re-challenging with osimertinib alone after it has clearly stopped working is not supported by current NCCN or ESMO guidance outside of a clinical trial. Ask your oncologist whether a trial exploring re-challenge is open for your specific resistance profile.
Why can an earlier EGFR inhibitor not be tried instead?
First-generation and second-generation EGFR inhibitors such as erlotinib, gefitinib, or afatinib were effective at an earlier stage because they targeted a different phase of EGFR resistance. Osimertinib itself was developed to overcome resistance that those earlier drugs caused. The resistance mechanisms that develop after osimertinib are mostly different again, and earlier-generation EGFR inhibitors do not have activity against them. Fourth-generation EGFR inhibitors designed for this setting are in clinical trials, but none is currently approved in India.
How quickly do we need to decide on the next treatment?
There is usually time to wait for resistance testing results before committing to a next-line treatment. If you are well and not experiencing rapid or symptomatic progression, that wait is generally worth taking, because the result can meaningfully change the recommendation. If your disease is progressing quickly or you are unwell, your oncologist may recommend starting chemotherapy while testing results are awaited, and adjusting if something targetable is identified. Ask your team directly how much time you have in your specific situation.
Should we be looking at clinical trials at this point?
Yes — this is one of the most important moments to do so. The osimertinib-resistant setting is one of the most active areas of lung cancer research, and trials investigating fourth-generation EGFR inhibitors, novel combinations, and bispecific antibodies are running. Some trials accept patients with a known resistance mechanism; others accept patients regardless of mechanism. Ask your oncologist whether any open trial applies to your situation, and whether referral to a centre with an active trial programme would be worth exploring.
What if testing cannot identify the resistance mechanism?
This happens in a proportion of patients. Platinum-based chemotherapy remains an option in that situation and does not depend on identifying a specific mechanism. Not finding a clear driver does not mean your cancer is untreatable — it means a targeted next step is not available right now. Liquid biopsy repeated as the disease evolves may reveal a mechanism later. Ask your oncologist whether repeat testing makes sense as your situation changes.
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How long does osimertinib usually work before resistance develops?
There is no single figure that applies to all patients, and NCCN and ESMO guidance does not quote one, because the range across studies is wide. Factors including which EGFR mutation is present, whether osimertinib was given first-line or after prior therapy, and individual cancer biology all influence duration. Ask your oncologist what was seen in trials that match your situation most closely — that is a more useful frame than a population average.
Is a liquid biopsy enough or do I need a tissue biopsy?
A liquid biopsy can identify several resistance mechanisms without an invasive procedure, and it is a reasonable starting point. However, it does not detect all resistance types — histological transformation to small cell lung cancer, for example, requires tumour tissue to be identified. Most oncologists recommend both where tissue is safely accessible. If a tissue biopsy is not possible, a liquid biopsy still provides useful information and is better than no testing at all.
What is amivantamab and is it relevant after osimertinib?
Amivantamab is a bispecific antibody that targets both EGFR and MET. Clinical trials have studied amivantamab-based combinations in patients who progressed on osimertinib, and ESMO and NCCN have discussed this data in their guidance. Availability and regulatory approval in India should be confirmed with your oncologist, as access differs from trial availability. Whether it applies to you depends on your resistance profile and your fitness for treatment.
Will chemotherapy still work after osimertinib?
Yes. Platinum-based chemotherapy works by a completely different mechanism from osimertinib, and its activity is not negated by EGFR resistance. ESMO and NCCN guidance lists platinum-based chemotherapy as a standard option after osimertinib progression. The benefit seen varies between individuals, and your oncologist can explain what that treatment is expected to achieve in your particular situation.
Is there anything CION can do at this stage?
Yes. Resistance assessment, coordination of biopsy, and next-line systemic therapy including chemotherapy are available at CION centres. Immunotherapy where indicated is administered as day care. Imaging including PET-CT is coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy. If a clinical trial is being considered, your oncologist will advise whether referral to another centre is needed.
Should we seek a second opinion at this point?
A second opinion after osimertinib progression is entirely reasonable, and most oncologists will support the request. The decisions at this stage involve genuine complexity, and a second opinion at a centre with experience in EGFR resistance and access to clinical trials may add useful perspective. Ask for your complete records — pathology reports, imaging, and all molecular test results including any resistance biopsy — so a second opinion can be based on the full picture.